Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre,Randomized,Double-Blind,Double-Dummy,3period,6Seq,Crossover,Active&Placebo,SD PD Study to Evaluate Therapeutic Equivalence of Test Tiotropium Bromide Inh. Powder to Reference SPIRIVA® HANDIHALER in Subjects w/COPD*

NCT05161156 is registered in ClinicalTrials.gov with Phargentis SA as lead sponsor.

NCT NCT05161156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05161156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre,Randomized,Double-Blind,Double-Dummy,3period,6Seq,Crossover,Active&Placebo,SD PD Study to Evaluate Therapeutic Equivalence of Test Tiotropium Bromide Inh. Powder to Reference SPIRIVA® HANDIHALER in Subjects w/COPD*
Lead sponsor
Phargentis SA
Phase
Phase 3
Overall status
Completed
Start date
March 24, 2022
Completion date
November 29, 2022
Enrollment
306 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

copd